Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

Katsuyuki Hotta; Kiichiro Ninomiya; Eiki Ichihara; Katsuyuki Kiura

doi:10.1007/s10147-018-1344-x

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

Katsuyuki Hotta, Kiichiro Ninomiya, Eiki Ichihara, Katsuyuki Kiura

University Hospital

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.

Original language	English
Pages (from-to)	41-45
Number of pages	5
Journal	International Journal of Clinical Oncology
Volume	24
Issue number	1
DOIs	https://doi.org/10.1007/s10147-018-1344-x
Publication status	Published - Jan 22 2019

Keywords

Lung cancer
Re-biopsy
Treatment

ASJC Scopus subject areas

Surgery
Hematology
Oncology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1007/s10147-018-1344-x

Fingerprint Dive into the research topics of 'Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice'. Together they form a unique fingerprint.

Cite this

@article{3c9169167c094f9b801c525990cde492,

title = "Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice",

abstract = "The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.",

keywords = "Lung cancer, Re-biopsy, Treatment",

author = "Katsuyuki Hotta and Kiichiro Ninomiya and Eiki Ichihara and Katsuyuki Kiura",

note = "Funding Information: KH has received honoraria outside the current work from AstraZeneca, Ono Pharmaceutical, Astellas, Novartis, BMS, MSD, Eli Lilly Japan, Daiichi-Sankyo Pharmaceutical, Boehringer-Ingelheim, Nihon Kayaku, Taiho Pharmaceutical, and Chugai Pharmaceutical. KH has also received research funding outside the current work from AstraZeneca, Boehringer-Ingelheim, Ono Pharmaceutical, Astellas, Novartis, BMS, Eli Lilly Japan, MSD, and Chugai Pharmaceutical. KK has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Sanofi-Aventis.",

year = "2019",

month = jan,

day = "22",

doi = "10.1007/s10147-018-1344-x",

language = "English",

volume = "24",

pages = "41--45",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer Japan",

number = "1",

}

TY - JOUR

T1 - Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

AU - Hotta, Katsuyuki

AU - Ninomiya, Kiichiro

AU - Ichihara, Eiki

AU - Kiura, Katsuyuki

N1 - Funding Information: KH has received honoraria outside the current work from AstraZeneca, Ono Pharmaceutical, Astellas, Novartis, BMS, MSD, Eli Lilly Japan, Daiichi-Sankyo Pharmaceutical, Boehringer-Ingelheim, Nihon Kayaku, Taiho Pharmaceutical, and Chugai Pharmaceutical. KH has also received research funding outside the current work from AstraZeneca, Boehringer-Ingelheim, Ono Pharmaceutical, Astellas, Novartis, BMS, Eli Lilly Japan, MSD, and Chugai Pharmaceutical. KK has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Sanofi-Aventis.

PY - 2019/1/22

Y1 - 2019/1/22

N2 - The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.

AB - The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.

KW - Lung cancer

KW - Re-biopsy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85053234455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053234455&partnerID=8YFLogxK

U2 - 10.1007/s10147-018-1344-x

DO - 10.1007/s10147-018-1344-x

M3 - Review article

C2 - 30159691

AN - SCOPUS:85053234455

VL - 24

SP - 41

EP - 45

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 1

ER -

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this